Department of Molecular Microbiology & Immunology, School of Medicine, University of Missouri, Columbia, MO, United States.
Division of Animal Sciences, College of Agriculture, Food and Natural Resources, University of Missouri, Columbia MO, United States.
Front Cell Infect Microbiol. 2022 Aug 4;12:928704. doi: 10.3389/fcimb.2022.928704. eCollection 2022.
In the lungs of infected individuals, the downstream molecular signaling pathways induced by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are incompletely understood. Here, we describe and examine predictions of a model in which NOTCH may represent a central signaling axis in lung infection in Coronavirus Disease 2019 (COVID-19). A pathway involving NOTCH signaling, furin, ADAM17, and ACE2 may be capable of increasing SARS-CoV-2 viral entry and infection. NOTCH signaling can also upregulate IL-6 and pro-inflammatory mediators induced to hyperactivation in COVID-19. Furthermore, if NOTCH signaling fails to turn down properly and stays elevated, airway regeneration during lung healing can be inhibited-a process that may be at play in COVID-19. With specific NOTCH inhibitor drugs in development and clinical trials for other diseases being conducted, the roles of NOTCH in all of these processes central to both infection and healing merit contemplation if such drugs might be applied to COVID-19 patients.
在感染 SARS-CoV-2 的个体肺部中,其下游分子信号通路尚未完全阐明。在这里,我们描述并检验了一种模型的预测,该模型认为 NOTCH 可能是 2019 冠状病毒病(COVID-19)肺部感染中的中央信号轴。涉及 NOTCH 信号、furin、ADAM17 和 ACE2 的途径可能能够增加 SARS-CoV-2 病毒的进入和感染。NOTCH 信号还可以上调 IL-6 和促炎介质,使其在 COVID-19 中过度激活。此外,如果 NOTCH 信号不能正常下调并持续升高,肺部愈合过程中的气道再生可能会受到抑制,这一过程可能在 COVID-19 中发挥作用。鉴于正在开发针对其他疾病的特定 NOTCH 抑制剂药物并进行临床试验,考虑这些药物是否可应用于 COVID-19 患者,如果此类药物可能适用于 COVID-19 患者,则 NOTCH 在这些感染和愈合的关键过程中的作用值得考虑。